Brad Ringeisen
Executive Director, Innovative Genomics Institute
Brad Ringeisen is the executive director of Innovative Genomics Institute. He guides scientific and development strategy to link the development of gene-editing tools to affordable and accessible solutions in human health and climate. Previously, Ringeisen was director of the Biological Technologies Office at DARPA, overseeing research in genome editing, epigenetics, neurotechnology, food security and biomanufacturing as well as diagnostics and therapeutics development. There, his office was responsible for early investments in mRNA vaccines as well as a discovery platform that isolated one of the first monoclonal antibody treatments used during the COVID-19 pandemic. Prior to this, Ringeisen was the head of the Bioenergy and Biofabrication Section at the U.S. Naval Research Laboratory.
Previously
NOAA’s chief scientist talks with a conservation expert about ocean biodiversity, we hear a call to ensure the safety of climate tech, and The White House makes an announcemen...
Interested in gene-edited cows that burp less methane, drought resistant wheat, and lab-made palm oil that could reduce rainforest destruction? Learn more about these and othe...
Global decarbonization efforts require the world to double down on solutions in the agriculture sector. This panel will shine light on some of the solutions that promise to cu...